ALLK Dec 2024 2.500 put
| Previous close | 0.9500 |
| Open | 0.9500 |
| Bid | 1.2000 |
| Ask | 1.8500 |
| Strike | 2.50 |
| Expiry date | 2024-12-20 |
| Day's range | 0.9500 - 0.9500 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
GlobeNewswireAllakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 – SAN CARLOS, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced results fr
- GlobeNewswire
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024. Recent Allakos Events Initiated the randomized, double-blind, placebo-controlled Phase 1 trial of intravenous (IV) AK006 in patients with chronic spontaneous urticaria.Complet
Simply Wall St.Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
